Scarica l'app Stockscreener
56.57
0.55%
0.31
Pre-mercato:
56.90
0.33
+0.58%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché NVO Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$56.26
Aprire:
$56.85
Volume 24 ore:
17.19M
Relative Volume:
1.02
Capitalizzazione di mercato:
$251.37B
Reddito:
$46.69B
Utile/perdita netta:
$15.29B
Rapporto P/E:
16.48
EPS:
3.4329
Flusso di cassa netto:
$9.25B
1 W Prestazione:
+11.18%
1M Prestazione:
+18.20%
6M Prestazione:
-18.39%
1 anno Prestazione:
-32.12%
Intervallo 1D:
$56.23
$57.77
Intervallo di 1 settimana:
$51.41
$58.15
Portata 52W:
$43.08
$93.80
Novo Nordisk Adr Stock (NVO) Company Profile
Nome
Novo Nordisk Adr
Settore
Industria
Telefono
-
Indirizzo
-
Confronta NVO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NVO
Novo Nordisk Adr
|
56.57 | 249.99B | 46.69B | 15.29B | 9.25B | 3.4329 |
|
LLY
Lilly Eli Co
|
1,108.09 | 952.34B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
207.49 | 493.40B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
233.42 | 395.77B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
141.98 | 272.99B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
108.60 | 270.22B | 63.90B | 19.05B | 13.05B | 7.5596 |
Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-08 | Downgrade | Argus | Buy → Hold |
| 2025-10-27 | Ripresa | Jefferies | Underperform |
| 2025-10-01 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2025-09-29 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2025-09-17 | Aggiornamento | Berenberg | Hold → Buy |
| 2025-09-16 | Aggiornamento | Rothschild & Co Redburn | Neutral → Buy |
| 2025-09-09 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2025-08-13 | Aggiornamento | BNP Paribas Exane | Underperform → Neutral |
| 2025-08-05 | Downgrade | UBS | Buy → Neutral |
| 2025-07-31 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-07-30 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-04-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2025-03-13 | Aggiornamento | Kepler | Hold → Buy |
| 2025-03-03 | Downgrade | Stifel | Buy → Hold |
| 2025-02-12 | Iniziato | Morgan Stanley | Equal-Weight |
| 2025-01-06 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2024-04-12 | Iniziato | BMO Capital Markets | Outperform |
| 2024-01-23 | Iniziato | Morgan Stanley | Overweight |
| 2024-01-16 | Ripresa | UBS | Neutral |
| 2023-12-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-02 | Iniziato | Argus | Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2022-07-15 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-06-28 | Downgrade | UBS | Neutral → Sell |
| 2022-06-27 | Aggiornamento | Exane BNP Paribas | Underperform → Neutral |
| 2022-06-07 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-05-31 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-04-25 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2022-04-12 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2022-03-16 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-01-25 | Downgrade | Liberum | Hold → Sell |
| 2021-12-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-12-17 | Downgrade | Deutsche Bank | Buy → Hold |
| 2021-01-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2021-01-15 | Iniziato | Deutsche Bank | Buy |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-07-06 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-05-11 | Downgrade | UBS | Buy → Neutral |
| 2020-05-04 | Iniziato | Cowen | Market Perform |
| 2020-03-16 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2020-01-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-11-18 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-09-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-08-30 | Downgrade | Jefferies | Hold → Underperform |
| 2019-06-20 | Downgrade | Deutsche Bank | Buy → Hold |
| 2019-06-11 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2019-04-29 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-01-29 | Iniziato | Exane BNP Paribas | Outperform |
| 2018-12-11 | Ripresa | Jefferies | Hold |
| 2018-10-09 | Iniziato | Guggenheim | Buy |
| 2017-12-29 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2017-12-06 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2017-12-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2017-09-25 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| 2017-09-06 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
Mostra tutto
Novo Nordisk Adr Borsa (NVO) Ultime notizie
Best Oral Peptides for Weight Loss: Injectable vs Sublingual vs Daily Pill – Direct Meds Consumer Analysis - GlobeNewswire Inc.
European ADRs Rose In US Trading As Chip And Pharma Led - Finimize
Will Novo Nordisk A s (b Shares) Adrhedged stock benefit from infrastructure spending2026 world cup usa national team semifinals star players high defensive line winner prediction tactical review - Улправда
G-Protein Coupled Receptors (GPCRs) Market Size to Hit USD 6.04 Billion by 2032, Growing at a CAGR of 5.59% - GlobeNewswire Inc.
2 Tailwinds Behind Novo Nordisk Stock Heading Into 2026 - Finviz
Jim Cramer Shares Key Caveat For Novo Nordisk (NVO)'s Weight Loss Pill - Finviz
FDA Approves Novo Nordisk's Wegovy Pill: A Game Changer for 2026 - Finviz
The Truth About Novo Nordisk A/S (ADR): Is Wall Street’s Favorite ‘Skinny Stock’ Still Worth t - AD HOC NEWS
Why Novo Nordisk Stock Dropped on Monday - Finviz
Where is Novo Nordisk A/S (NVO) Headed? - Finviz
Novo Nordisk (NVO) Gets 9% Boost from Wegovy Pill OK - Finviz
Should You Invest in Ozempic Maker Novo Nordisk in 2026? - Finviz
What Does the Market Think About Novo Nordisk AS? - Sahm
The New York Stock Exchange | NYSE - NYSE
Novo Nordisk AS (NVO) Stock Price, Trades & News - GuruFocus
Why Novo Nordisk Stock Popped Today - Finviz
Novo Nordisk's Wegovy Pill Shakes Up Rivalry With Eli Lilly, Puts Health Care ETFs In Focus - Sahm
Novo Nordisk stock split: what’s next for NVO shares? - Capital.com
Eli Lilly Vs. Novo Nordisk: Which Stock Could Lead Pharma's 2026 Comeback - Sahm
Novo Nordisk Share Price Jumps After FDA Clears Wegovy Pill | Stock Market Today - Samco
Novo Nordisk surges after US approves weight loss pill - Sharecast.com
Novo Nordisk Shares Surge 7% In Tuesday Pre-Market After US FDA Approves Wegovy Pill - Sahm
Novo Nordisk stock jumps over 7% after weight loss drug Wegovy pill gets US FDA nod — Details here - livemint.com
Novo Nordisk, Starfighters Space, D-Wave Quantum, Sidus Space And ZIM Integrated Shipping: Why These 5 Stocks Are On Investors' Radars Today - Sahm
Should You Forget Novo Nordisk and Buy This Magnificent High-Yield Drug Stock Instead? - Finviz
How Novo Nordisk A s (b Shares) Adrhedged stock valuations compare to rivalsJuly 2025 Analyst Calls & Safe Entry Trade Signal Reports - Улправда
Tech Rally: Will Novo Nordisk A s (b Shares) Adrhedged stock maintain momentum in 2025July 2025 Volume & Low Risk High Reward Ideas - Улправда
Why Novo Nordisk A s (b Shares) Adrhedged stock remains resilientWeekly Stock Analysis & Risk Controlled Stock Alerts - Улправда
Will Novo Nordisk A s (b Shares) Adrhedged stock outperform value stocksJuly 2025 Momentum & High Yield Equity Trading Tips - Улправда
Novo Nordisk (NVO) Receives Positive Opinion For Wegovy By European Medicines Agency - Finviz
Novo Nordisk Files NDA for Next-Generation Obesity Drug CagriSema - Finviz
Targets Report: Will Novo Nordisk A s (b Shares) Adrhedged stock benefit from infrastructure spendingEarnings Performance Report & AI Forecasted Stock Moves - Улправда
Will Novo Nordisk A s (b Shares) Adrhedged stock maintain momentum in 2025Gap Down & Long-Term Safe Investment Ideas - Улправда
Resistance Check: How Novo Nordisk A s (b Shares) Adrhedged stock valuations compare to rivals2025 Institutional Moves & Stock Timing and Entry Methods - Улправда
Novo Nordisk (NVO) Fell Following a Profit Warning Release - Finviz
Better Buy in 2026: Novo Nordisk or Intuitive Surgical? - Finviz
Better Pharmaceutical Buy: Eli Lilly vs. Novo Nordisk - Finviz
Novo Nordisk Adr Azioni (NVO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.25%
3.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):